Marcin Czerwinski/LinkedIn;
Radoslaw Kaczmarek/LinkedIn
Mar 28, 2026, 17:01
Marcin Czerwinski: Neutralizing Anti-AAV Antibodies in Hemophilia B Gene Therapy
Marcin Czerwinski, Professor at Hirszfeld Institute of Immunology and Experimental Therapy, shared a post on LinkedIn about a recent article by Radoslaw Kaczmarek, adding:
“Radoslaw (Radek) Kaczmarek just wrote a great commentary about neutralizing anti-AAV antibodies (NAbs) in hemophilia B therapy that can block transduction, thereby abolishing efficacy.
It seems that this is not the case…”
Title: Hemophilia B gene therapy: a NAb-solute barrier overcome by AAV5
Author: Radoslaw Kaczmarek
Read the Full Article on RPTH Journal
Stay updated with Hemostasis Today.
-
Mar 28, 2026, 17:28James Crowley: Precision Cancer Therapy Advances
-
Mar 28, 2026, 17:27Volkmar Weissig: Cellular Uptake of Isolated Mitochondria and Its Implications for Mitochondrial Transfer
-
Mar 28, 2026, 17:25Alan Nurden: FNAIT Remains an Important Clinical Challenge in Inherited Bleeding Disorders
-
Mar 28, 2026, 17:24Michael Baria: Is PRP Disease Modifying in Osteoarthritis?
-
Mar 28, 2026, 17:07Wolfgang Miesbach: How Does Protein S Inhibition Restore Hemostasis in von Willebrand Disease?
-
Mar 28, 2026, 16:56Sonia Wolf: Reproductive Outcomes in Women with Sickle Cell Disease
-
Mar 28, 2026, 16:42Kalpana Gupta Shekhawat: Low Ferritin and Its Impact on Dopamine Signaling
-
Mar 28, 2026, 16:34Seema Dawood: Acquired Platelet Dysfunction with Eosinophilia – Bleeding Despite Normal Platelet Count
-
Mar 28, 2026, 16:18Mohamed F Doheim: AI-Driven Stroke Triage Boosts Workflow and EVT Use Across Multicenter Network